All news

Biotech stocks rally as drug innovation boom returns

CNBC · RSS · · AI-summarised by FinFlash

Biotech stocks are rallying as clinical trial wins, merger and acquisition activity and new drug technologies revive the sector after a prolonged slump. Analysts point to exchange-traded funds and individual stocks as ways to gain exposure to the renewed interest in drug development. For investors, the shift signals improving sentiment toward a sector that had lagged the broader market.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.